Mitoxantrone
Mostrando 1-12 de 34 artigos, teses e dissertações.
-
1. Castration-resistant prostate cancer: systemic therapy in 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease with prostatectomy and radiation therapy, some patients develop metastatic disease and die. Although andr
Clinics. Publicado em: 2012
-
2. Influência do tratamento na incapacidade da esclerose múltipla: estudo aberto, retrospectivo e não randomizado em longo prazo
A eficácia das medicações imunossupressivas (IMS) e imunomoduladoras (IMM) na esclerose múltipla (MS) tem sido relatada em diversos estudos. Essas medicações podem reduzir o número de surtos e de lesões observadas nos estudos de ressonância magnética. Entretanto, o efeito dessas medicações na progressão da incapacidade em período acima de quatr
Arquivos de Neuro-Psiquiatria. Publicado em: 2010-08
-
3. Collection of peripheral blood progenitor cell after administration of cyclophosphamide and granulocyte-colony stimulating factor (GCSF): an analysis of 307 patients / Coleta de células progenitoras hematopoéticas de sangue periférico após administração de ciclofosfamida e fator estimulador de colônias de granulócitos (G-CSF): uma análise de 307 pacientes
Inadequate stem cells mobilization is seen in 10-30% of patients undergoing autotransplantation for hematologic malignancies. Factors affecting peripheral blood progenitor cell (PBSC) mobilization have not been clearly established. We retrospectively reviewed the data of patients treated by autologous bone marrow transplantation (BMT) with the aim to identif
Publicado em: 2008
-
4. Definição de alvos moleculares em diferenciação, morte e resistencia de celulas tumorais / Defenition of molecular targets indifferentiation, death and resisteance in cancer cells
Cancer therapy efficiency, under several aspects, even with the progress of pharmacotechnology, remains as a challenge for the medicine. According to this factor, new agents that act on specific target, present low side-effects and prevent cancer cells escaping from death induction, are extremely desirable. In this work, 3 aspects of antitumoral prop
Publicado em: 2007
-
5. Mitoxantrone na esclerose múltipla secundária progressiva relato de 18 casos
Hidrocloridrato de mitoxantrone (Novantrone®) é um antracenedione utilizado como o agente mais recente de uma longa linha de imunossupressivos gerais estudados em esclerose múltipla (EM). Realizamos revisão de dados clínicos, laboratoriais, de neuroimagem e ecocardiografia de 18 pacientes, no período de fevereiro de 2001 a março de 2004, a partir de u
Arquivos de Neuro-Psiquiatria. Publicado em: 2005-06
-
6. Leucemia mielóide aguda induzida por mitoxantrone: relato de caso
Mitoxantrone (MX) é uma agente imunossupressor utilizado nas formas progressivas secundárias de esclerose múltipla (EM) ou formas surto-remissão sem resposta com outras formas de tratamento (p.ex. beta-interferon, acetato de glatirâmer). Com o uso desta medicação, ocorre uma incidência maior, embora pequena, de desenvolvimento de leucemia mielóide a
Arquivos de Neuro-Psiquiatria. Publicado em: 2005-06
-
7. Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla: I. As evidências para o uso de imunossupressores, plasmaférese e transplante autólogo de células tronco
O tratamento da esclerose múltipla (EM) com imunossupressores teve início na década de 60. As observações laboratoriais e clínicas de que a doença tinha um caráter inflamatório induziu os clínicos a utilizarem medicamentos citostáticos e imunossupressores. Foram assim incorporados ao arsenal terapêutico da EM as drogas utilizadas em outras doenç
Arquivos de Neuro-Psiquiatria. Publicado em: 2002-09
-
8. Dynamic Assessment of Mitoxantrone Resistance and Modulation of Multidrug Resistance by Valspodar (PSC833) in Multidrug Resistance Human Cancer Cells
P-glycoprotein (Pgp), a member of the ATP-binding cassette transporter family, is one of the major causes for multidrug resistance (MDR). We report using confocal microscopy to study the roles of Pgp in mediating the efflux of the anticancer agent mitoxantrone and the reversal of MDR by the specific Pgp inhibitor valspodar (PSC833). The net uptake and ef
American Society for Pharmacology and Experimental Therapeutics.
-
9. Formation of DNA adducts by formaldehyde-activated mitoxantrone.
Recent studies with the anthracycline Adriamycin have demonstrated its activation by formaldehyde and subsequent binding to DNA in vitro. Since formaldehyde levels are known to be higher in cells of myeloid origin and the structurally related drug mitoxantrone is most effective against cancers of myeloid origin, this indicates a possible role of formaldehyde
-
10. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
OBJECTIVE: To evaluate the efficiency of mitoxantrone in multiple sclerosis. METHODS: Forty two patients with confirmed multiple sclerosis, selected as having a very active disease on clinical and MRI criteria were randomised to receive either mitoxantrone (20 mg intravenously (IV) monthly) and methylprednisolone (1 g iv monthly) or methylprednisolone alone
-
11. Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts
Recently we have found that mitoxantrone, like Adriamycin, can be activated by formaldehyde and subsequently form adducts which stabilise double-stranded DNA in vitro. This activation by formaldehyde may be biologically relevant since formaldehyde levels are elevated in those tumours in which mitoxantrone is most cytotoxic. In vitro transcription analysis re
Oxford University Press.
-
12. DNA sequence specificity of mitoxantrone.
An in vitro transcription assay was used to determine the sequence specificity of binding of mitoxantrone to a 497 bp fragment of DNA containing the lac UV5 promoter. Transcriptional blockages of the E. coli RNA polymerase were observed dominantly prior to 5'-CpA sequences (64% occurrence), and to a lesser extent 5'-CpG sequences (29%). Overall, 93% of all b